The Journal of Urology
Volume 166, Issue 4 , Pages 1311-1315, October 2001

SELECT: THE NEXT PROSTATE CANCER PREVENTION TRIAL

From the Section of Urologic Oncology, Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, Division of Urology, University of Texas Health Sciences Center and Southwest Oncology Group, San Antonio and Department of Clinical Cancer Prevention, M. D. Anderson Cancer Center, Houston, Texas, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, and Cancer Prevention Studies Branch, Division of Clinical Sciences, National Cancer Institute, Washington, D. C.

Purpose

Growing evidence implies that selenium and vitamin E may decrease the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized prospective double-blind study designed to determine whether selenium and vitamin E decrease the risk of prostate cancer in healthy men.

Materials and Methods

The preclinical and epidemiological evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of the 2 agents were included in the current analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the SELECT schema.

Results

Preclinical, epidemiological and phase III data imply that selenium and vitamin E have potential efficacy for prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial shows the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT.

Conclusions

SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment in the study is planned to begin in 2001 with final results anticipated in 2013.

Key Words:  prostate , prostatic neoplasms , chemoprevention , selenium , vitamin E

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Accepted for publication May 4, 2110.Presented at annual meeting of Society of Urologic Oncology, Atlanta, Georgia, April 29, 2000.

PII: S0022-5347(05)65759-X

The Journal of Urology
Volume 166, Issue 4 , Pages 1311-1315, October 2001

Article Tools

* Image Usage & Resolution